These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 32710321)
1. PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection. Pandey P; Zhao C; Liu B Methods Mol Biol; 2020; 2204():133-143. PubMed ID: 32710321 [TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Blom DJ; Dent R; Castro RC; Toth PP Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264 [TBL] [Abstract][Full Text] [Related]
7. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
8. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Page MM; Watts GF Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830 [TBL] [Abstract][Full Text] [Related]
9. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP; J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735 [TBL] [Abstract][Full Text] [Related]
10. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Mahmood T; Shapiro MD Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589 [TBL] [Abstract][Full Text] [Related]